UnknownNot Applicable

A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

China50 participantsStarted 2021-10-08

Plain-language summary

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. The age of subjects are between 18-90 years old (including 18 and 90 years old);
✓. All kinds of tumor diseases of subjects are acceptable;
✓. All kinds of PD-1 immune checkpoint blockades or dosages are acceptable;
✓. The subjects knew about the experiment and signed the informed consent voluntarily;
✓. The subjects plan to receive PD-1 immune checkpoint blockades and potentially to be treated for over 3 months;
✓. The subjects complicated with atherosclerotic carotid plaques.

✕. Subjects stop receiving or changing the PD-1 immune checkpoint blockades during follow-up;
✕. Subjects are reluctant to continue to be involved in this study;
✕. Known pregnant and lactating women;
✕. The parameters (e.g., CCA intima-media, ICA intima-media or carotid plaque burden) could not be calculated because of the quality of ultrasound image;
✕. Other situations that the researchers judged were not suitable for inclusion.

The mean intima-media thickness of the common carotid artery

Timeframe: 3 months

The maximum intima-media thickness of the internal carotid artery

Timeframe: 3 months

Carotid plaque burden

Timeframe: 3 months

NCT IDNCT05123287

SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-06-01

Jianan Wang, MD, PhD

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. The age of subjects are between 18-90 years old (including 18 and 90 years old);
✓. All kinds of tumor diseases of subjects are acceptable;
✓. All kinds of PD-1 immune checkpoint blockades or dosages are acceptable;
✓. The subjects knew about the experiment and signed the informed consent voluntarily;
✓. The subjects plan to receive PD-1 immune checkpoint blockades and potentially to be treated for over 3 months;
✓. The subjects complicated with atherosclerotic carotid plaques.

✕. Subjects stop receiving or changing the PD-1 immune checkpoint blockades during follow-up;
✕. Subjects are reluctant to continue to be involved in this study;
✕. Known pregnant and lactating women;
✕. The parameters (e.g., CCA intima-media, ICA intima-media or carotid plaque burden) could not be calculated because of the quality of ultrasound image;
✕. Other situations that the researchers judged were not suitable for inclusion.